ライフサイエンスコーパス: antiviral antibody

1 , hypergammaglobulinemia, and high levels of antiviral antibody.

2 e HIV-1 envelope, with the goal of eliciting antiviral antibodies.

3 ship between antigenicity and sensitivity to antiviral antibodies.

4 ed for innate B cell-stimulating factors and antiviral antibodies.

5 virus infection and defects in production of antiviral antibodies.

6 nsfection, coincident with the appearance of antiviral antibodies.

7 r, they became beneficial in the presence of antiviral antibody (Ab).

8 ecrudescence is prevented by the transfer of antiviral antibody (Ab).

9 and to isolate several broadly neutralizing antiviral antibodies against highly variable pathogens s

10 Prevalence of antiviral antibodies agreed with known infection rates f

11 Antiviral antibody also enables ADV to infect macrophage

12 titis B virus (HBV) is completely cleared by antiviral antibodies and specific cytotoxic T lymphocyte

13 -hBUGT, there was a marked inhibition of the antiviral antibody and Ad-specific cytotoxic T lymphocyt

14 een baseline IgE levels and the magnitude of antiviral antibody and CD4(+) T-cell responses was obser

15 with hypergammaglobulinemia, high levels of antiviral antibody and circulating immune complexes, and

16 Antiviral antibody and interferon-gamma have major roles

17 in PKCtheta+/+ and PKCtheta-/- mice, whereas antiviral antibody and T-helper cell cytokine production

18 treatments that diminish viral replication (antiviral antibody) and pulmonary inflammation (anti-inf

19 titer at the time of peak lesion formation, antiviral antibodies, and cellular immune responses.

20 e a general strategy to boost the potency of antiviral antibodies, and, because membrane affinity is

21 orphological evidence of the localization of antiviral antibodies at anatomical sites relevant to suc

22 tameric gH complex is the primary target for antiviral antibodies by vaccination.

23 roducing S and MHVR, because fusion-blocking antiviral antibodies did not prevent it.

24 ccurate quantitation of chiropteran maternal antiviral antibody half-life, provide fundamental baseli

25 Following reports of elevated antiviral antibodies in MS patient sera and viral DNA de

26 ty for evaluation of the efficacies of novel antiviral antibodies in protecting and restoring placent

27 ata directly demonstrate a critical role for antiviral antibody in protecting from the selective outg

28 early control of CNS virus replication, that antiviral antibody is critical for clearance from the br

29 nscutaneous vaccination but elicited similar antiviral antibody levels and T-cell responses in both t

30 Antiviral antibodies limit B19 infection in vivo; howeve

31 Herein, we tested whether antiviral antibody-mediated suppression of virus replica

32 To determine if passively acquired antiviral antibodies modulate virus transmission and dis

33 Expression of APRIL and antiviral antibodies of IgA and IgM but not IgG isotype

34 While antiviral antibody plays a key role in resistance to acu

35 Antiviral antibody production during respiratory syncyti

36 eased plasma cell maturation, and negligible antiviral antibody production.

37 ce cell-mediated responses but no detectable antiviral antibodies, protected a fraction of cats again

38 restriction is a key selective event for the antiviral antibody response and is probably important fo

39 levels of virus replication and undetectable antiviral antibody response and required sequence change

40 The antiviral antibody response to HCMV infection is complex

41 the magnitude of this effector cell-mediated antiviral antibody response was inversely associated wit

42 ation and undetectable or weak and transient antiviral antibody response.

43 t epitope specificities contributes to HIV-1 antiviral antibody responses and is important to induce

44 effectiveness is complicated by induction of antiviral antibody responses and rapid host clearance of

45 These observations indicate that antiviral antibody responses are critical in maintaining

46 dily with a half-life of 8-15 years, whereas antiviral antibody responses are maintained for up to 75

47 , strength, and kinetics of epitope-specific antiviral antibody responses in vaccine trials with a si

48 A vaccine capable of stimulating protective antiviral antibody responses is needed to curtail the gl

49 Antiviral antibody responses remained stable between 1-7

50 responses that declined slowly over time and antiviral antibody responses that remained stable for de

51 Antiviral antibody responses were remarkably stable, wit

52 infected but had a delayed viremia, enhanced antiviral antibody responses, and a slower disease cours

53 fected, the immunized animals mounted better antiviral antibody responses, controlled virus levels mo

54 envelope glycoproteins do not elicit strong antiviral antibody responses, particularly against prima

55 ferentiation of Ag-primed CD4(+) T cells and antiviral antibody responses.

56 reflects an adaptation to facilitate strong antiviral antibody responses.

57 rsisted in inoculated rabbits despite higher antiviral antibody responses.

58 ry S. pneumoniae infection exaggerates early antiviral antibody-secreting cell formation, and at late

59 Functional studies with human monoclonal antiviral antibodies showed that conformational epitopes

60 No elimination of antiviral antibodies tested was seen.

61 As indicated by the isotypes of antiviral antibodies, the T-B dipeptide preferentially i

62 nsmission, as measured by plasma viremia and antiviral antibodies, through 10 weeks postchallenge.

63 complete adjuvant was able to induce strong antiviral antibody titers and a high frequency of specif

64 ouse genotype, virus persistence in the CNS, antiviral antibody titers, mortality, and the severity o

65 ion promoted MHC class I expression, reduced antiviral antibody titers, promoted viral persistence, a

66 infections were defined as having no or low antiviral antibody titers.

67 strated that vaccination elicited functional antiviral antibodies to multiple neutralizing sites in r

68 etween viral infections and T1D by profiling antiviral antibodies using a high-throughput immunoprote

69 throughput method to comprehensively analyze antiviral antibodies using immunoprecipitation and massi

70 m dilution is most appropriate for screening antiviral antibody, using a positive-to-negative ratio o

71 IgM and IgG antiviral antibodies were detected in the serum of the d

72 Antiviral antibodies were not observed postvaccination.

73 newborns that had transplacentally acquired antiviral antibodies were protected against mucosal SIV

74 HRES-1/p28 is a target of cross-reactive antiviral antibodies, whereas HRES-1/Rab4 regulates the

75 and the challenging precedent of correlating antiviral antibodies with disease association, these ant